COMPANY
Darmerica, LLC
Darmerica, LLC: bulk ingredient labeler, warning letter recipient for BPC-157, Bremelanotide, CJC-1295, GHK-Cu, Ipamorelin, KPV, Leuprolide, Liraglutide, Melanotan II, MOTS-c, Oxytocin, Semaglutide, Sermorelin, Setmelanotide, Tesamorelin, Tirzepatide, Vancomycin, Retatrutide, as stated by public registers.
Also written as: DARMERICA, LLC.
BULK INGREDIENT LABELER
Lists the bulk active ingredient with FDA (NDC directory).
| BPC-157 | BPC-157 Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
|---|---|
| Bremelanotide | Bremelanotide Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| CJC-1295 | CJC-1295 Acetate, BULK INGREDIENT Regulator openFDA |
| GHK-Cu | Tripeptide-1 (GHK-Cu), BULK INGREDIENT Regulator openFDA |
| Ipamorelin | Ipamorelin Acetate, BULK INGREDIENT Regulator openFDA |
| KPV | KPV Acetate, BULK INGREDIENT Regulator openFDA |
| Leuprolide | Leuprolide Acetate, BULK INGREDIENT Regulator openFDA |
| Liraglutide | Liraglutide, BULK INGREDIENT Regulator openFDA |
| Melanotan II | Melanotan II Acetate, BULK INGREDIENT Regulator openFDA |
| MOTS-c | MOTs-C Acetate, BULK INGREDIENT Regulator openFDA |
| Oxytocin | Oxytocin, BULK INGREDIENT Regulator openFDA |
| Semaglutide | Semaglutide, BULK INGREDIENT Regulator openFDA |
| Sermorelin | Sermorelin Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Setmelanotide | Setmelanotide (RM-493) Acetate, BULK INGREDIENT Regulator openFDA |
| Tesamorelin | Tesamorelin Acetate, BULK INGREDIENT Regulator openFDA |
| Tirzepatide | Tirzepatide, BULK INGREDIENT Regulator openFDA |
| Vancomycin | Vancomycin HCl, BULK INGREDIENT Regulator openFDA |
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Retatrutide | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded, 2025-12-08 Regulator FDA warning letters |
|---|
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.